Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer by Judith Gulikers, Jeroen Bruinsma, Janna Schoenmaekers, Safiye Dursun, Vivianne Tjan-Heijnen, Robin van Geel, Sander Croes, Lizza Hendriks

Get full text

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC by Mandy Jongbloed, MD, Valentina Bartolomeo, MD, Martina Bortolot, MD, Shahan Darwesh, MD, Jarno W.J. Huijs, MD, Safiye Dursun, MD, Juliette Degens, MD, PhD, Ben E.E.M. van den Borne, MD, PhD, Maggy Youssef-El Soud, MD, PhD, Marcel Westenend, MD, PhD, Cordula Pitz, MD, PhD, Dirk K.M. De Ruysscher, MD, PhD, Lizza E.L. Hendriks, MD, PhD

Get full text